Quick Takeaways
- Steven D. Rubin has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $17,059,506.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Steven D. Rubin
- Location
- Miami, FL
- Summary
- The estimated net worth of Steven D. Rubin is at least $17,059,506 dollars as of 17 Feb 2026. Steven D. Rubin is the Director of Red Violet, Inc. and owns shares of Red Violet, Inc. (RDVT) stock worth about $8.65M. Steven D. Rubin is the Executive VP-Administration, Director of OPKO HEALTH, INC. and owns shares of OPKO HEALTH, INC. (OPK) stock worth about $8.38M. Steven D. Rubin is the Director of Entera Bio Ltd. and owns shares of Entera Bio Ltd. (ENTXW) stock worth about $22.4K. Steven D. Rubin is the Director of Eloxx Pharmaceuticals, Inc. and owns shares of Eloxx Pharmaceuticals, Inc. stock worth about $5.4K.
- Signature
- /s/ Dana Yaacov-Garbeli, Attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Steven D. Rubin and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Red Violet, Inc. ($8,650,838).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Steven D. Rubin
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| RDVT | Red Violet, Inc. | Director | $8,650,838 | 19 Dec 2025 | ||
| OPK | OPKO HEALTH, INC. | Executive VP-Administration, Director | $8,380,918 | 27 May 2025 | ||
| ENTXW, ENTX | Entera Bio Ltd. | Director | $22,350 | +$19,450 | +671% | 12 Feb 2026 |
| ELOX | Eloxx Pharmaceuticals, Inc. | Director | $5,400 | 24 Jan 2025 | ||
| COCP | Cocrystal Pharma, Inc. | Director | 09 Jan 2026 | |||
| NAGE | Niagen Bioscience, Inc. | Director | 24 Jun 2025 |
Insider Transactions Reported by Steven D. Rubin:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.